Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant systemic therapy for early breast cancer.

J Crown1, L Norton

  • 1Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, New York 10021.

Seminars in Surgical Oncology
|September 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO open·2025
Same author

Correction: Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells.

British journal of cancer·2025
Same author

Parallel EEG-fNIRS assessments of covert cognition in behaviorally non-responsive ICU patients: A multi-task feasibility study in a case of acute motor sensory axonal neuropathy.

Journal of neurology·2025
Same author

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer.

Breast cancer research and treatment·2021
Same journal

Preoperative chemoradiation for locally advanced rectal cancer: rationale, technique, and results of treatment.

Seminars in surgical oncology·2003
Same journal

Preoperative chemoradiation for locally advanced rectal adenocarcinoma-the University of Florida experience.

Seminars in surgical oncology·2003
Same journal

Postoperative adjuvant therapy for pancreatic cancer.

Seminars in surgical oncology·2003
Same journal

Conformal chemoradiation for primary and metastatic liver malignancies.

Seminars in surgical oncology·2003
Same journal

Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer.

Seminars in surgical oncology·2003
Same journal

Combined modality therapy in esophageal cancer: the Memorial experience.

Seminars in surgical oncology·2003
See all related articles

Systemic therapy, including chemotherapy and hormonal therapy, is crucial for breast cancer management. Treatment decisions for node-negative patients require further research to optimize adjuvant therapy selection.

Area of Science:

  • Oncology
  • Medical Oncology

Background:

  • Systemic therapy is integral to managing primary breast cancer with axillary lymph node metastasis.
  • Emerging data indicate its utility even in node-negative patients, though selection criteria are debated.

Purpose of the Study:

  • To review current practices and ongoing investigations in adjuvant systemic therapy for breast cancer.
  • To delineate the roles of chemotherapy and hormonal therapy based on menopausal status, receptor status, and risk stratification.

Main Methods:

  • Review of current literature and clinical trial data on adjuvant systemic therapy for breast cancer.
  • Analysis of treatment efficacy based on patient characteristics (menopausal status, lymph node involvement, receptor status) and risk of relapse.

Main Results:

Related Experiment Videos

  • Chemotherapy is standard for premenopausal patients; tamoxifen is used for postmenopausal patients with receptor-positive tumors.
  • Chemotherapy may augment tamoxifen benefits in some postmenopausal women.
  • For low-risk patients (0-3 positive nodes), 6 months of cyclophosphamide, methotrexate, and 5-fluorouracil is a benchmark.
  • Doxorubicin-based regimens benefit high-risk patients.
  • High-dose chemotherapy with autologous bone marrow support is under investigation for very high-risk patients (≥10 positive nodes).

Conclusions:

  • Adjuvant systemic therapy is essential for most breast cancer patients, particularly those with lymph node involvement.
  • Personalized treatment selection, considering menopausal status, receptor status, and nodal burden, is critical.
  • Further research is needed to refine criteria for adjuvant therapy in node-negative breast cancer.